Research
Considering benefits and harms of duloxetine for treatment of stress urinary incontinence: a meta-analysis of clinical study reports
Emma Maund, Louise Schow Guski and Peter C. Gøtzsche
CMAJ February 06, 2017 189 (5) E194-E203; DOI: https://doi.org/10.1503/cmaj.151104
Emma Maund
Nordic Cochrane Centre, Rigshospitalet, Copenhagen, Denmark
MSc PhDLouise Schow Guski
Nordic Cochrane Centre, Rigshospitalet, Copenhagen, Denmark
MDPeter C. Gøtzsche
Nordic Cochrane Centre, Rigshospitalet, Copenhagen, Denmark
MDData supplements
Related Articles
- Braillon, A. (2017). Duloxetine: urinary incontinence and marketing authorization incontinence. CMAJ, 189(9), E373. Accessed May 14, 2024. https://doi.org/10.1503/cmaj.732561.
In this issue
Article tools
Respond to this article
Considering benefits and harms of duloxetine for treatment of stress urinary incontinence: a meta-analysis of clinical study reports
Emma Maund, Louise Schow Guski, Peter C. Gøtzsche
CMAJ Feb 2017, 189 (5) E194-E203; DOI: 10.1503/cmaj.151104
Jump to section
Related Articles
Cited By...
- Current and Emerging Pharmacological Targets and Treatments of Urinary Incontinence and Related Disorders
- What have antidepressants been tested for? A systematic review
- Presentation of benefits and harms of antidepressants on websites: A cross-sectional study
- Benefits and harms of antipsychotic drugs in drug-naïve patients with psychosis: A systematic review
- Drop-out rates in placebo-controlled trials of antidepressant drugs: A systematic review and meta-analysis based on clinical study reports
- Duloxetine: urinary incontinence and marketing authorization incontinence
- Secrecy or transparency? The future of regulatory trial data